Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Profound Medical's Enterprise Value is C$319.28 Mil.
Profound Medical's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was C$-52.37 Mil. Therefore, Profound Medical's EV-to-EBIT ratio for today is -6.10.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Profound Medical's Enterprise Value is C$319.28 Mil.
Profound Medical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was C$-51.69 Mil. Therefore, Profound Medical's EV-to-EBITDA ratio for today is -6.18.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Profound Medical's Enterprise Value is C$319.28 Mil.
Profound Medical's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was C$25.91 Mil. Therefore, Profound Medical's EV-to-Revenue ratio for today is 12.32.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Profound Medical's Enterprise Value is C$319.28 Mil.
Profound Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was C$-52.92 Mil. Therefore, Profound Medical's EV-to-FCF ratio for today is -6.03.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Profound Medical (TSX:PRN) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Profound Medical's current Enterprise Value is C$319.28 Mil.
Profound Medical's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-52.37 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Profound Medical's current Enterprise Value is C$319.28 Mil.
Profound Medical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-51.69 Mil.
Profound Medical's current Enterprise Value is C$319.28 Mil.
Profound Medical's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$25.91 Mil.
Profound Medical's current Enterprise Value is C$319.28 Mil.
Profound Medical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-52.92 Mil.
Profound Medical's current Enterprise Value is C$319.28 Mil.
Profound Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-52.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profound Medical Enterprise Value Related Terms
Profound Medical Enterprise Value Historical Data
* Premium members only.
The historical data trend for Profound Medical's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSX:PRN vs ABT, SYK, MDT: Enterprise Value Comparison
For the Medical Devices subindustry, Profound Medical's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profound Medical Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Profound Medical's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Profound Medical's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of C$319.28 Mil mean?
Profound Medical (TSX:PRN) has a Enterprise Value of C$319.28 Mil as of Jul. 07, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Profound Medical and its competitors.
Is Profound Medical's Enterprise Value too high?
Profound Medical's current Enterprise Value is C$319.28 Mil. Overall, Profound Medical has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's Enterprise Value compare to ABT and SYK?
Profound Medical's Enterprise Value of C$319.28 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Profound Medical and its competitors. Profound Medical's current Enterprise Value is C$319.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (TSX:PRN) is currently considered Possible Value Trap. The stock's GF Value™ is C$20.37, compared to a current price of C$10.46 — trading 48.6% below its estimated fair value. The current Enterprise Value is C$319.28 Mil. Profound Medical's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Profound Medical (TSX:PRN), the current Enterprise Value is C$319.28 Mil as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profound Medical (TSX:PRN) Overvalued in 2026?
Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued.
The current stock price of C$10.46 is trading 48.6% below its estimated GF Value™ of C$20.37.
GuruFocus considers Profound Medical to be Possible Value Trap.
Key valuation signals for TSX:PRN:
Enterprise Value: C$319.28 Mil
GF Value™: C$20.37 vs. price of C$10.46 (48.6% below fair value)
No single metric tells the full story. See the TSX:PRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
68GF Score
Get the complete analysis for TSX:PRN
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:PRN has been successfully added to your 
